Figure 4.

Concentrations of the CASQ1 protein and serum levels of CASQ1 antibodies titers.

Notes: (A) Mean ± SE (control =166.3±31.8, GO =91.8±42.9, and GH =66.0±17.0 pmol/mg protein) concentrations of the CASQ1 protein in patients and control subject; rs2275703 polymorphism is present in both patients and controls. The mean concentration of CASQ1 was significantly reduced in patients with GH (Mann–Whitney test: **P=0.007) compared with the control subjects. (B) Comparing serum levels of CASQ1 antibodies titers in nine patients with GO and 21 patients with GH with 18 control subjects; rs2275703 polymorphism is present in both patients and controls. Mean ± SE (control =496.4±37.1, GO =346.5±116.2, and GH =297.6±44.3) antibody titers in patients and control subjects. The mean serum CASQ1 antibodies titers was significantly reduced in patients with GO (*P=0.019) and also significantly reduced in patients with GH (**P=0.003)

Abbreviations: SE, standard error; GO, Graves’ ophthalmopathy; GH, Graves’ hyperthyroidism; CASQ1, calsequestrin; OD, optical density.